|
Business Combinations - Additional Information (Detail) (USD $)
|
3 Months Ended | 6 Months Ended | 6 Months Ended | 1 Months Ended | 6 Months Ended | 6 Months Ended | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Mar. 30, 2013
|
Mar. 24, 2012
|
Mar. 30, 2013
|
Mar. 24, 2012
|
Jan. 03, 2013
|
Mar. 30, 2013
Property, plant and equipment [Member]
|
Mar. 30, 2013
Land and buildings [Member]
|
Dec. 31, 2012
Chindex Medical Limited [Member]
|
Aug. 01, 2012
Gen-Probe Incorporated [Member]
|
Mar. 30, 2013
Gen-Probe Incorporated [Member]
|
Jan. 31, 2013
Gen-Probe Incorporated [Member]
|
Oct. 31, 2012
Gen-Probe Incorporated [Member]
|
Mar. 30, 2013
Gen-Probe Incorporated [Member]
Minimum [Member]
|
Mar. 30, 2013
Gen-Probe Incorporated [Member]
Maximum [Member]
|
Mar. 30, 2013
Gen-Probe Incorporated [Member]
Developed technology [Member]
|
Mar. 30, 2013
Gen-Probe Incorporated [Member]
Customer contract [Member]
|
Mar. 30, 2013
Gen-Probe Incorporated [Member]
Trade names [Member]
|
|
| Business Acquisition [Line Items] | |||||||||||||||||
| Cash paid per share | $ 82.75 | ||||||||||||||||
| Amount paid to shareholders | $ 3,800,000,000 | ||||||||||||||||
| Amount paid to equity award holders | 169,000,000 | ||||||||||||||||
| Net debt obtained by the Company to finance the acquisition | 3,480,000,000 | ||||||||||||||||
| Direct transaction costs incurred | 34,300,000 | ||||||||||||||||
| Remaining fair value of stock options assumed to be recognized as compensation expense | 23,200,000 | ||||||||||||||||
| Vesting period | 3 years 6 months | ||||||||||||||||
| Risk free interest rate | 0.50% | 0.70% | 0.50% | 0.70% | 0.41% | ||||||||||||
| Expected volatility | 39.90% | ||||||||||||||||
| Expected life | 3 years 7 months 6 days | ||||||||||||||||
| Dividend yield, rate | 0.00% | ||||||||||||||||
| Weighted average fair value of stock options, per share | $ 7.07 | ||||||||||||||||
| Adjustment to valuation of intangibles | 2,000,000 | ||||||||||||||||
| Agreement to sell LIFECODES business to Immucor | 85,000,000 | ||||||||||||||||
| Contingent payment of an additional amount based on future revenue results | 10,000,000 | ||||||||||||||||
| Gain on the sale of LIFECODES business | 900,000 | 900,000 | |||||||||||||||
| Assets held-for-sale | 2,200,000 | ||||||||||||||||
| Property and equipment | 600,000 | 600,000 | |||||||||||||||
| Discount rate used for cash flow projections | 10.00% | 12.00% | |||||||||||||||
| In-process Research and Development expense | 227,000,000 | ||||||||||||||||
| In-process research and development, value | 27,000,000 | 7,000,000 | |||||||||||||||
| Total cost of completion of IPR&D projects | 46,000,000 | ||||||||||||||||
| Discount rate | 12.00% | ||||||||||||||||
| Expected number of years for project completion | 4 years | ||||||||||||||||
| Finite-lived intangible assets, estimated useful life, years | 12 years 6 months | 13 years | 11 years | ||||||||||||||
| Fair value adjustment to increase the carrying amount | 107,900,000 | 70,600,000 | |||||||||||||||
| Net purchase price | $ 4,500,000 | $ 3,972,176,000 | |||||||||||||||